Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based CURx Pharmaceuticals has entered into a global license agreement with Gilead Sciences for development of Fosfomycin: Tobramycin for Inhalation (FTI) intended for the treatment of Pseudomonas aeruginosa lung infection in cystic fibrosis (CF) patients.
Subscribe to our email newsletter
The company said that FTI, a combination of fosfomycin and tobramycin, is ready for Phase III clinical trials, having completed a Phase II trial in CF patients.
FTI is formulated as a liquid for inhalation with an aerosol device.
In Phase II trials, FTI, which is formulated as a liquid for inhalation with an aerosol device, was shown to be safe and to effectively maintain improvement in lung function achieved with Cayston in CF patients with Pseudomonas aeruginosa infection.
FTI has showed antibiotic activity against multiple pathogenic bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), in preclinical studies.
CURx founder and CEO Dinu Sen said this is a great acquisition for the company which allows it to expand its portfolio and also to provide another inhaled therapeutic to the cystic fibrosis community.
"Clinical trials in CF patients with Pseudomonas aeruginosa infection have demonstrated FTI’s safety and efficacy," Sen said.
"Future trials may pave the way for its use against a range of bacterial infections in CF – there is an unmet need for antibiotics with such characteristics."